Products from BPS Bioscience require a minimum order value above 400€
Background: STEAP1 (six transmembrane epithelial antigen of the prostate 1), also called STEAP, belongs to the STEAP family of metalloproteinases, which are involved in iron and copper regulation and other processes. It is a cell surface protein expressed in several types of cancer, most notably prostate cancer where STEAP1 was identified as a cancer specific cell-surface antigen. The upregulation of STEAP1 is linked to promotion of cancer cell proliferation and metastatic transformation and higher STEAP expression levels are correlated with poor survival. The differential expression of STEAP1 between cancer cells and normal tissue makes STEAP1 a promising target for antibody-drug-conjugate (ADC) development. The use of STEAP1 CAR (chimeric antigen receptor)-T cell therapy combined with tumor-localized IL-12 therapy is also under study for the treatment of prostate cancer.
Description: Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa.
Format: Aqueous buffer solution.
Formulation: Supplied as a 0.22 μm filtered solution in NaAC, 0.2 M L-Arginine, pH 5.5.
Host Cell Line: CHO
Purity: ≥90%
Storage Stability: Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.
Target: STEAP1
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
Deutsch
English
